Clinical Trial Update: A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement [Phase 2]

View source ↗

Summary

A Phase 2 trial update for LDK378 in non-small cell lung cancer with ROS1 rearrangement is reported; the status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Yonsei University | Conditions: Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | Phase 2 | Status: UNKNOWN